Adjuvant alectinib is a new treatment strategy for resected ALK-positive NSCLC
Alectinib is the first ALK inhibitor to significantly improve DFS in a phase III trial across disease stages
RET inhibitor nearly doubled PFS in RET fusion-positive advanced/metastatic NSCLC
Results from the LIBRETTO-431 trial reinforce the use of selpercatinib as the first-line choice and are likely to widen patient access to treatment
Adding amivantamab to chemotherapy prolongs PFS in untreated EGFR exon 20 insertion-mutated advanced NSCLC
The bispecific EGFR/MET-directed monoclonal antibody looks set to become the standard of care in this setting, but toxicity has to be managed carefully
New data support perioperative nivolumab for patients with resectable NSCLC
CheckMate 77T demonstrates significantly improved event-free survival with neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab compared with chemotherapy and adjuvant placebo
An ESMO study reveals that poor quality of real-world data from oncology studies is still an issue
Scarcity of prospective data was reported as well as a limited use of real-world evidence as definitive evidence to regulatory approval decisions of targeted therapies in Europe
Adoptive cell therapy using TILs shows clinically meaningful and durable efficacy in advanced mucosal melanoma
Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma
Updated hallmarks of cancer guide treatment development
Old and emerging traits of cancer provide a common set of principles that may help research shape future progress
First-line pembrolizumab combination significantly improves PFS in HER2-positive metastatic G/GEJ adenocarcinoma
Adding immunotherapy to standard of care shows benefit compared with placebo and is confirmed to be practice-changing for this patient population
Are we over-treating patients with locally advanced rectal cancer?
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
TIL therapy – an opportunity for a few centres?
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients